早期肺癌患者分期及辅助治疗的新问题课件.ppt

NSCLC, non-small-cell lung cancer; OS, overall survival. ? Here are the ANITA study results: There was an improvement in median survival in the observation arm from close to 44?months to close to 66?months in the vinorelbine plus cisplatin arm, with a P value of .017 and a hazard ratio of 0.8. * * ECOG PS, Eastern Cooperative Oncology Group performance score; NSCLC, non-small-cell lung cancer. ? This is the third study—JBR10. This is a study of adjuvant vinorelbine and cisplatin for patients with resected NSCLC that was conducted primarily by the National?Cancer?Institute of Canada Clinical Trials Group. In this study, patients were randomized again to vinorelbine and cisplatin vs observation. This particular study was open for patients with either IB or IIA disease. * NSCLC, non-small-cell lung cancer. ? Here are the results for the JBR.10 study: There was a very significant improvement in survival, with a survival of 69% at 5 years in the chemotherapy arm vs 54% at 5 years in the observation arm. This magnitude of improvement is clearly similar—if not better—to what we see in terms of the improvement in survival for the adjuvant treatment of breast or colon cancer. * AUC, area under the curve; NSCLC, non-small-cell lung cancer. ? This was the fourth study, the CALGB study, which involved only patients with stage?IB NSCLC. They were resected and then randomized to observation alone or to adjuvant chemotherapy consisting of paclitaxel or carboplatin. * HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival. ? Here are the results for the CALGB study: There was an improvement in median survival, from 78?months to 95?months, but this time it was not statistically significant; the P value was 0.125. Why might that be? This may be because the study was unique in several different ways. * Carbo, carboplatin; Cis, cisplatin; HR, hazard ratio; NSCLC, non-small-cell lung cancer; OS, overall survival. ? First, out of all of these studies, it was th